The global scourge you never heard of Wolfgang Kerler
Although a safe and effective vaccine has been available for eight
years now, 1.6 million people still die from pneumococcal diseases every
year, making it the number one vaccine-preventable cause of death
worldwide. More than half of the victims are children.
“Pneumococcal diseases are probably the greatest killer worldwide
that you rarely hear about,” Orin Levine, executive director of the
PneumoADIP project (Pneumococcal vaccines Accelerated Development and
Introduction Plan) at Johns Hopkins Bloomberg School of Public Health,
told IPS.
“Although they are causing as many deaths as tuberculosis and more
than malaria, they do not get the same attention.”
There are only 26 countries among the 193 members of the World Health
Organisation (WHO) where most or all children are being immunised
against pneumococcal diseases such as pneumonia, meningitis or sepsis.
Twenty-four of these countries are high-income countries representing
less than one percent of the cases of illness.
“The overwhelming majority of deaths occur in Sub-Saharan Africa and
South Asia,” Levine said. “Together those two areas account for almost
three-quarters of child deaths caused by pneumococcal diseases.” The
above numbers are the result of research on the worldwide introduction
of pneumococcal conjugate vaccine (PCV) released by the U.S. Centres for
Disease Control and Prevention (CDC) and WHO Friday. The research
revealed that no low-income country offers PCV to children as a part of
its national immunisation program or has PCV in widespread use —
although at least one child dies of pneumococcal diseases in poor
countries every minute.
“Pneumococcal disease is found all over the globe, but all too often
strikes those who are young, poor and least equipped to fight it,” said
Matthew Moore, medical epidemiologist at the CDC.
“While optimal diagnosis and management of pneumococcal disease saves
lives, many children and adults do not have access to this care.”
According to Levine from PneumoADIP, the lack of public awareness is the
major reason for these deficits. “If there is a disease you have never
heard of and it is not a priority to prevent it, there is not much
interest in funding the efforts to fight it,” he said.
For poor countries, the high costs of vaccines have been an obstacle
to their large-scale introduction. However, during the next 10 years,
global immunisation funding for new vaccines and immunisation systems
could be as much as 8 billion dollars, according to estimates released
by the Pneumococcal Awareness Council of Experts (PACE).
“We call on governments internationally to take advantage of this
progress in health care and ensure life-saving pneumococcal vaccines are
available to the people who need it most,” Levine said.
He stressed that although “the price of action will be measured in
dollars, the price of inaction will be measured in child deaths that
could have been prevented.”
The GAVI Alliance (formerly known as the Global Alliance for Vaccines
and Immunisations) — a project of which PneumoADIP is a member — has
dedicated 1.5 billion dollars “to make pneumococcal vaccines available
for a subsidised price for the world’s poorest countries”, Levine said.
>From early 2009 on, Rwanda and Gambia are likely to be the first two
countries to benefit from this programme. Six other countries — Central
African Republic, Democratic Republic of Congo, Guyana, Honduras, Kenya,
and Nicaragua — have also been approved by GAVI for the introduction of
PCV into national immunisation programmes.
The pneumococcus is a bacterium that causes serious infections like
meningitis, pneumonia and sepsis. In developing countries, even half of
those children who receive medical treatment will die. Every second
surviving child will have some kind of disability.
One of the reasons why Sub-Saharan African countries are especially
hard hit by pneumococcal diseases is the fact that persons infected with
HIV are up to 300 times more likely to have a pneumococcal disease than
those who are HIV-negative. More than 60 percent of HIV-infected persons
are living in Sub-Saharan Africa. In 2000, a new pneumococcal conjugate
vaccine became available which is now licensed in more than 90
countries. Studies in the United States revealed that the country has
almost completely eliminated pneumococcal diseases of children since
infants began receiving routine vaccination eight years ago.
To raise awareness and to urge governments, donors and industry
alike, more than 100 professional medical societies, institutions and
organisations from around the world joined the Pneumococcal Awareness
Council of Experts (PACE) Friday and made a unified call to action.
Levine, who is a co-chair of Pace, stressed that “We are just beginning
to take the steps that are necessary to combat pneumococcal disease. And
while we are encouraged of what we begin to see, we must further expand
these efforts.”
IPS
|